Ozempic 1 mg GoQuick Pen from Novo Nordisk is a single-use, pre-filled injection device containing semaglutide, a glucagon-like peptide-1 (GLP-1) receptor agonist used to treat type 2 diabetes and aid in weight management. Administered once weekly via subcutaneous injection, it works by boosting insulin secretion, reducing glucagon production, and slowing gastric emptying. These combined effects help curb appetite and decrease cravings for high-fat foods. Beyond blood sugar control, it offers proven cardiovascular advantages — lowering the risk of heart attack, stroke, and cardiovascular-related mortality — making it a valuable choice for both athletes and individuals focused on optimizing health and physical appearance.
This medication is well-suited for adults with type 2 diabetes, including those engaged in sports or fitness, who aim to stabilize blood glucose, manage body weight, and enhance overall metabolic function. The ergonomic GoQuick Pen design ensures ease of use, providing convenience for those balancing intense training schedules with ongoing health management. With its anti-inflammatory properties and protective benefits for both cardiovascular and kidney health, Ozempic supports active lifestyles, promotes a leaner physique, and aids in recovery without the necessity of gym-based interventions.
Ozempic (semaglutide) helps reduce elevated blood sugar by stimulating insulin release, suppressing glucagon secretion, and delaying stomach emptying. It naturally controls appetite, lowers food intake, and reduces preference for high-fat foods, supporting effective weight loss. Clinical research indicates that it improves lipid profiles, decreases systolic blood pressure, and reduces inflammation. In animal studies, semaglutide slowed the progression of atherosclerosis by preventing aortic plaque formation and minimizing plaque inflammation.
Application and dosage Ozempic
dosage regimen for non-diabetics (weight management):
dosage regimen for type 2 diabetes:
method of administration: subcutaneous (abdomen, thigh, or upper arm)
advice: use a new NovoFine Plus needle for each injectionrotate injection sitesadminister any time of day, with or without foodstore unopened pens in refrigerator (2°C–8°C)after first use, store at room temperature (up to 30°C) for up to 56 dayscourse duration as prescribed by a doctor.
use in patients with multiple endocrine neoplasia type 2 or history of medullary thyroid cancer
use without medical consultation if history of diabetic ketoacidosis, pancreatitis, kidney disease, or diabetic retinopathy
sharing pens or needles to prevent infection
abrupt discontinuation without medical advice
combining with other glp-1 agonists without supervision.
| Characteristics | |
| Active ingridient | Semaglutide |
| Purpose | Improved glycemic control in type 2 diabetes, weight management support |
| Suitable for beginners | Yes (min dosage) |
| Suitable for men over 50 | According to the doctor's prescription |
| Suitable for women over 50 | According to the doctor's prescription |
There are no reviews for this product.